Organon & Co. (NYSE:OGN) Sees Unusually-High Trading Volume - Here's Why

Organon & Co. (NYSE:OGN - Get Free Report) shares saw an uptick in trading volume on Tuesday . 3,247,765 shares were traded during mid-day trading, an increase of 48% from the previous session's volume of 2,197,288 shares.The stock last traded at $16.06 and had previously closed at $16.92.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Evercore ISI raised Organon & Co. to a "strong-buy" rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. downgraded shares of Organon & Co. from a "neutral" rating to an "underweight" rating and upped their price target for the company from $18.00 to $20.00 in a report on Friday, September 6th.

Organon & Co. Price Performance

The company has a debt-to-equity ratio of 60.05, a current ratio of 1.64 and a quick ratio of 1.17. The firm has a market capitalization of $4.24 billion, a PE ratio of 3.27, a P/E/G ratio of 0.81 and a beta of 0.84. The company has a 50-day moving average price of $19.26 and a 200-day moving average price of $20.12.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a return on equity of 2,437.43% and a net margin of 20.30%. The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same period in the prior year, the business earned $0.78 earnings per share. Organon & Co.'s revenue for the quarter was up 4.1% on a year-over-year basis. Sell-side analysts forecast that Organon & Co. will post 4.04 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Tuesday, November 12th will be paid a $0.28 dividend. The ex-dividend date of this dividend is Tuesday, November 12th. This represents a $1.12 annualized dividend and a yield of 6.80%. Organon & Co.'s payout ratio is currently 22.22%.

Institutional Trading of Organon & Co.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. LSV Asset Management grew its stake in shares of Organon & Co. by 47.3% during the 2nd quarter. LSV Asset Management now owns 6,610,768 shares of the company's stock valued at $136,843,000 after buying an additional 2,121,940 shares during the period. Wedge Capital Management L L P NC acquired a new position in shares of Organon & Co. in the 2nd quarter valued at about $33,573,000. Kahn Brothers Group Inc. increased its position in Organon & Co. by 3,242.4% during the 1st quarter. Kahn Brothers Group Inc. now owns 1,180,204 shares of the company's stock worth $22,188,000 after purchasing an additional 1,144,894 shares in the last quarter. Boston Partners purchased a new position in Organon & Co. in the first quarter valued at approximately $19,306,000. Finally, AQR Capital Management LLC lifted its position in Organon & Co. by 39.8% during the second quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company's stock valued at $71,905,000 after buying an additional 988,336 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.